Please assess the completion status of the following clinical trial:

Trial Title: Transpulmin Suppository and Guaiacol Compared to Transpulmin Syrup in Pediatric Participants With Productive Cough

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants and their guardians to accept the inclusion of the research participant in the study and agree to the terms proposed in the Informed Consent Form / Informed Assent Form, by signing the Informed Consent Form and Informed Assent Form by guardians and signature of Informed Assent Form by the participant, if possible;~* Participants aged ≥ (greater than or equal) to 02 years and ≤ (less than or equal) to 06 years, 11 months and 29 days of any ethnicity, class or social group;~* Participants diagnosed with acute respiratory disease of upper respiratory viral etiology (UAI) defined by medical researcher / sub-investigator, starting less than or equal to 48 hours prior to inclusion in the study;~* Participants with productive cough, sputum and lung snoring, so that the participant can be rated with a score of at least sporadic / light in specific score in accordance with paragraph 7.2.1. (Table 06 of the Protocol).~Exclusion Criteria:~* Participants treated with antibiotics;~* Clinical presence of bacterial infection of the upper airways and / or pulmonary (bacterial sinusitis, pneumonia, etc.);~* Participants with unproductive cough (dry cough);~* Treatment with immunosuppressants;~* Participating in the research that has participated in clinical trial protocols in the last twelve (12) months (National Board of Health- Resolution 251 of 07 August 1997, Part III, sub-item J), unless the investigator considers that there may be a direct benefit to it;~* Participants requiring multidrug treatment;~* Presence of other concomitant lung diseases that interfere, in the investigator's opinion on the study results;~* History hypersensitivity to components of the study drugs (suppository Transpulmin, Suppository of Guaiacol, Transpulmin syrup and Paracetamol);~* Subjects with pathologies that interfere with pulmonary function, such as cerebral palsy or muscular atrophies;~* Any medical or further processing (example: physiotherapy) that can interfere with the study objectives and / or participant safety;~* Participants with severe hepatic renal function disorders;~* Participants with x-ray chest compatible with bacterial infection framework;~* Participants with hemogram suggestive of bacterial infection;~* Medical history and / or changes in laboratory tests, clinical, physical and / or radiological that, judged by investigators, could compromise the participant's health or the reliability of data;~* Participants with previous diagnosis of diabetes mellitus type 01 or type 02;~* Participants diagnosed with porphyria;~* Participants who are in prohibited medication as described in item 6.9.1. of the Protocol.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- Transpulmin suppository (Type: EXPERIMENTAL): It is a rectal suppository that is manufactured by Aché S.A. and which is composed of camphor, eucalyptol, guaiacol and menthol.~The rectal suppositories will be dispensed to 90 participants of this group within a cartridge. Each cartridge contains one strip with five suppositories.~The participant must manage 1 suppository in the morning and 1 at night via rectal suppository (12/12h).~The duration of treatment may be up to 03 or 07 days, depending on the visit discharge.
- Guaiacol suppository (Type: EXPERIMENTAL): It is a rectal suppository that is manufactured by Aché S.A. and consists of guaiacol.~The rectal suppositories will be dispensed to 90 participants of this group within a cartridge. Each cartridge contains one strip with five suppositories.~The participant must manage 1 suppository in the morning and 1 at night via rectal suppository (12/12h).~The duration of treatment may be up to 03 or 07 days, depending on the visit discharge.
- Transpulmin syrup (Type: ACTIVE_COMPARATOR): It is a syrup which is manufactured by Aché S.A. and which is composed of guaifenesin.~Transpulmin syrup will be dispensed to 90 participants of this group in a bottle of 150ml plus a dosing cup.~The participant shall administer 7,5ml orally every 4 hours, The duration of treatment may be up to 07 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy